1-3 of 3
Fang Xiang
Close
Sort by
Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Jun Long, Ming-Yuan Jia, Wei-Yue Fang, Xin-Jie Chen, Li-Li Mu, Zhong-Yu Wang, Yan Shen, Ru-Fang Xiang, Li-Ning Wang, Ling Wang, Chuan-He Jiang, Jie-Ling Jiang, Wen-Jun Zhang, Yi-Dan Sun, Li Chang, Wen-Hui Gao, Ying Wang, Jun-Min Li, Deng-Li Hong, Ai-Bin Liang, Jiong Hu
Journal: Blood
Blood (2020) 135 (17): 1472–1483.
https://doi.org/10.1182/blood.2019003538
Published: 2020
Includes: Supplemental data
Journal Articles

Rationale and Design of a Phase II Open-Label, Multicenter Study to Assess the Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Adult Patients with Sickle Cell Disease

Julie Kanter, MD, Brian Elliott, Denis Weber, Chiaki Tanaka, Fang Xiang, Kenneth I Ataga, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4782.
https://doi.org/10.1182/blood.V130.Suppl_1.4782.4782
Published: 2017
Journal Articles

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

Marc S Raab, MD, Enrique M. Ocio, Sheeba K. Thomas, M.D., Andreas Günther, Daniel Lebovic, MD, Shaji K Kumar, MD, Andrzej J. Jakubowiak, MD, PhD, Dongweon Song, Fang Xiang, David Hynds, K. Gary Vanasse, M.D., Yeow Tee Goh, MD
Journal: Blood
Blood (2013) 122 (21): 3186.
https://doi.org/10.1182/blood.V122.21.3186.3186
Published: 2013